Indaptus Therapeutics Inc (INDP)
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker INDP. The company focuses on developing immunotherapy candidates for cancer and viral diseases. Its lead clinical program is Decoy20, a product being studied for potential single-agent and combination use in a range of indications, including lymphoma, hepatocellular, colorectal and pancreatic tumors, advanced solid tumors, chronic hepatitis B, and HIV infection. The company was previously known as Intec Parent, Inc. and adopted its current name in August 2021. Indaptus Therapeutics is headquartered in New York, New York.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-INDP
|
$1.52
|
-39.8% Downside
|
Overvalued
|
$10
|
296.0% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-15.3x
|
230.5x
|
—
|
278.6 M
|
286.1 M
|
0.0%
|
2.9%
|
99.7
|
—
|
89.0%
|
